JPH0160455B2 - - Google Patents
Info
- Publication number
- JPH0160455B2 JPH0160455B2 JP54012152A JP1215279A JPH0160455B2 JP H0160455 B2 JPH0160455 B2 JP H0160455B2 JP 54012152 A JP54012152 A JP 54012152A JP 1215279 A JP1215279 A JP 1215279A JP H0160455 B2 JPH0160455 B2 JP H0160455B2
- Authority
- JP
- Japan
- Prior art keywords
- milk
- type
- patients
- antibodies
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 235000013336 milk Nutrition 0.000 claims description 88
- 239000008267 milk Substances 0.000 claims description 88
- 210000004080 milk Anatomy 0.000 claims description 88
- 241000894006 Bacteria Species 0.000 claims description 25
- 108060003951 Immunoglobulin Proteins 0.000 claims description 24
- 102000018358 immunoglobulin Human genes 0.000 claims description 24
- 241000283690 Bos taurus Species 0.000 claims description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 7
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 241000186427 Cutibacterium acnes Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 240000000366 Melilotus officinalis Species 0.000 claims 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 1
- 235000020247 cow milk Nutrition 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 39
- 206010039073 rheumatoid arthritis Diseases 0.000 description 34
- 230000003053 immunization Effects 0.000 description 30
- 238000002649 immunization Methods 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 239000000902 placebo Substances 0.000 description 15
- 229940068196 placebo Drugs 0.000 description 15
- 206010003246 arthritis Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 229940072221 immunoglobulins Drugs 0.000 description 10
- 238000004062 sedimentation Methods 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 230000009931 harmful effect Effects 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 3
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 3
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 229960004544 cortisone Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 229940031348 multivalent vaccine Drugs 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010036030 Polyarthritis Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 208000030428 polyarticular arthritis Diseases 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003271 Arthritis salmonella Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108700029181 Bacteria lipase activator Proteins 0.000 description 1
- 241000421809 Brisaster fragilis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000489861 Maximus Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 208000012696 congenital leptin deficiency Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001078 no known side-effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020200 pasteurised milk Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940072689 plaquenil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87514078A | 1978-02-06 | 1978-02-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS54113425A JPS54113425A (en) | 1979-09-05 |
JPH0160455B2 true JPH0160455B2 (nl) | 1989-12-22 |
Family
ID=25365266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP1215279A Granted JPS54113425A (en) | 1978-02-06 | 1979-02-05 | Protecting and treating agent for rheumatism like arthritis |
Country Status (10)
Country | Link |
---|---|
JP (1) | JPS54113425A (nl) |
CH (1) | CH651210A5 (nl) |
DE (1) | DE2904044C2 (nl) |
DK (1) | DK158138C (nl) |
FR (1) | FR2416015A1 (nl) |
GB (1) | GB2013691B (nl) |
HK (1) | HK30283A (nl) |
IT (1) | IT1116524B (nl) |
NL (1) | NL7900766A (nl) |
SE (1) | SE448344B (nl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE33565E (en) * | 1978-02-06 | 1991-04-02 | Stolle Research And Development Corporation | Prevention and treatment of rheumatioid arthritis |
US4732757A (en) * | 1978-02-06 | 1988-03-22 | Stolle Research And Development Corporation | Prevention and treatment of rheumatoid arthritis |
AU558931B2 (en) * | 1981-02-26 | 1987-02-12 | Unilever Plc | A process and apparatus for the recovery of immunoglobulins |
EP0064103B1 (en) * | 1981-04-28 | 1985-11-06 | The Stolle Research And Development Corporation | Method of obtaining an anti-inflammatory bovine milk |
JP2561234B2 (ja) * | 1981-05-12 | 1996-12-04 | スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション | 抗炎症剤 |
JPS58154513A (ja) * | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
US4636384A (en) * | 1982-06-03 | 1987-01-13 | Stolle Research & Development Corporation | Method for treating disorders of the vascular and pulmonary systems |
EP0127712B1 (en) * | 1983-06-07 | 1989-01-11 | The Stolle Research And Development Corporation | Deodorant containing bacterial antibodies |
JPS6112629A (ja) * | 1984-06-28 | 1986-01-21 | Lion Corp | 口腔内組成物 |
EP0300102B1 (en) * | 1987-07-21 | 1993-03-24 | The Stolle Research And Development Corporation | Improved method of obtaining immune regulatory factors by mammal immunization |
JP2664906B2 (ja) * | 1987-08-13 | 1997-10-22 | ストール・リサーチ・アンド・デイベロップメント・コーポレーション | 改良された哺乳類の免疫法 |
JP2002542205A (ja) * | 1999-04-19 | 2002-12-10 | リチャード ワイスバート、 | 貯蔵ヒト免疫グロブリンおよび制酸剤の経口投与による成人リウマチ様関節炎の処置 |
WO2002026258A2 (en) * | 2000-09-28 | 2002-04-04 | Research Corporation Technologies, Inc. | Treatment of immune-mediated diseases by oral administration of plasma fractions |
AU2002309486A1 (en) * | 2001-01-30 | 2002-10-15 | The Lauridsen Group, Incorporated | Methods and compositions for modulating the immune system of animals |
EP1357942A2 (en) * | 2001-01-30 | 2003-11-05 | The Lauridsen Group Incorporated | Methods and compositions for treatment of immune dysfunction disorders |
JP4960632B2 (ja) * | 2006-01-10 | 2012-06-27 | 学校法人北里研究所 | 免疫ミルク組成物を有効成分とする単純ヘルペスウイルス感染症治療予防用組成物 |
JP5361132B2 (ja) * | 2006-03-10 | 2013-12-04 | 国立大学法人信州大学 | 免疫グロブリンgを含有する経口用免疫調節剤、その製造方法及び経口用免疫調節剤を配合してなる飲食品 |
JP2008179572A (ja) * | 2007-01-25 | 2008-08-07 | Shinshu Univ | 免疫グロブリンFcフラグメントレセプタータンパク及び/又は免疫グロブリンFcフラグメントレセプター様タンパク産生抑制剤及びその使用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136326A (ja) * | 1974-09-24 | 1976-03-27 | Komatsu Seiren Co | Seikeigorufubooru |
JPS51139617A (en) * | 1975-05-29 | 1976-12-02 | Green Cross Corp:The | A process for preparing a remedy for intestinal infectious diseases |
JPS521014A (en) * | 1975-06-17 | 1977-01-06 | Stolle Res & Dev | Pharmaceutically acceptable carrier containing milk immunoglobulin |
JPS5381613A (en) * | 1976-12-28 | 1978-07-19 | Green Cross Corp:The | Remedies for enteral infection diseases |
JPS53130411A (en) * | 1977-04-15 | 1978-11-14 | Nestle Sa | Production of immunoglobulin containing protein concentrate |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136326B1 (nl) * | 1965-10-24 | 1976-10-07 | ||
DE1617769A1 (de) * | 1967-06-10 | 1971-04-01 | Rehm Eberhard | Verfahren zur Gewinnung von spezifischen Antikoerper enthaltender Milch und daraus hergestellter Praeparate |
-
1979
- 1979-01-30 SE SE7900798A patent/SE448344B/sv not_active IP Right Cessation
- 1979-01-31 NL NL7900766A patent/NL7900766A/nl not_active Application Discontinuation
- 1979-02-02 FR FR7902807A patent/FR2416015A1/fr active Granted
- 1979-02-02 DE DE2904044A patent/DE2904044C2/de not_active Expired
- 1979-02-02 GB GB7903836A patent/GB2013691B/en not_active Expired
- 1979-02-05 JP JP1215279A patent/JPS54113425A/ja active Granted
- 1979-02-05 IT IT47888/79A patent/IT1116524B/it active
- 1979-02-06 DK DK049479A patent/DK158138C/da not_active IP Right Cessation
- 1979-02-06 CH CH1168/79A patent/CH651210A5/de not_active IP Right Cessation
-
1983
- 1983-08-25 HK HK302/83A patent/HK30283A/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5136326A (ja) * | 1974-09-24 | 1976-03-27 | Komatsu Seiren Co | Seikeigorufubooru |
JPS51139617A (en) * | 1975-05-29 | 1976-12-02 | Green Cross Corp:The | A process for preparing a remedy for intestinal infectious diseases |
JPS521014A (en) * | 1975-06-17 | 1977-01-06 | Stolle Res & Dev | Pharmaceutically acceptable carrier containing milk immunoglobulin |
JPS5381613A (en) * | 1976-12-28 | 1978-07-19 | Green Cross Corp:The | Remedies for enteral infection diseases |
JPS53130411A (en) * | 1977-04-15 | 1978-11-14 | Nestle Sa | Production of immunoglobulin containing protein concentrate |
Also Published As
Publication number | Publication date |
---|---|
FR2416015B1 (nl) | 1983-06-17 |
IT1116524B (it) | 1986-02-10 |
SE448344B (sv) | 1987-02-16 |
CH651210A5 (de) | 1985-09-13 |
SE7900798L (sv) | 1979-08-07 |
IT7947888A0 (it) | 1979-02-05 |
DK158138C (da) | 1990-08-27 |
NL7900766A (nl) | 1979-08-08 |
DK158138B (da) | 1990-04-02 |
DE2904044C2 (de) | 1986-02-06 |
DE2904044A1 (de) | 1979-08-30 |
GB2013691A (en) | 1979-08-15 |
DK49479A (da) | 1979-08-07 |
JPS54113425A (en) | 1979-09-05 |
FR2416015A1 (fr) | 1979-08-31 |
GB2013691B (en) | 1982-08-18 |
HK30283A (en) | 1983-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4732757A (en) | Prevention and treatment of rheumatoid arthritis | |
JPH0160455B2 (nl) | ||
US5585098A (en) | Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants | |
KR100365252B1 (ko) | 위장 손상의 치료 방법 | |
Reiter | Antimicrobial systems in milk | |
US5017372A (en) | Method of producing antibody-fortified dry whey | |
Bellamy et al. | Immune-mediated emigration of neutrophils into the lumen of the small intestine | |
WO1997020577A1 (en) | Improved therapeutic formulation and method | |
Yoder et al. | Immunotherapy of neonatal septicemia | |
KR20000048855A (ko) | 닭의 난황 항체를 경구 투여하여 질병을 치료하는 방법 | |
JP2000512634A (ja) | 下痢の治療 | |
EP0706400A1 (en) | Therapeutic formulation and method | |
Narayanan et al. | A planned prospective evaluation of the anti‐infective property of varying quantities of expressed human milk | |
US20210196825A1 (en) | Composition and Methods for Treating Acute Diarrhea and Enteric | |
Keusch | Nutritional effects on response of children in developing countries to respiratory tract pathogens: implications for vaccine development | |
Trenev | Probiotics: Nature's Internal Healers | |
USRE33565E (en) | Prevention and treatment of rheumatioid arthritis | |
Rawal et al. | Role of colostrum in gastrointestinal infections | |
Sheldrake et al. | Immune defences at mucosal surfaces in ruminants | |
Isaacson, M., Levy, D., Bubb, HD, Louw, JA & Genis | Unsusual cases of human plague in Southern Africa | |
EP3212664A1 (en) | Manufacture and use of hyperimmune egg pc2 | |
JP2912451B2 (ja) | ハチミツのワクチンとしての用途 | |
US6770280B1 (en) | Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product | |
JP3150162B2 (ja) | 経口日和見感染症防止治療用組成物 | |
Dean | Hyperimmune eggs capture natural immune support |